Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465792 | 0.88 | CCR2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4CCR2 | |
| SCHEMBL30396325 | 0.88 | CCR2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4CCR2 | |
| SCHEMBL8307596 | 0.87 | CCR2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4CCR2 | |
| SCHEMBL2827164 | 0.87 | GLS (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4CCR2 | |
| SCHEMBL21198393 | 0.87 | CCR2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4MAPKAPK2 | |
| SCHEMBL29988292 | 0.87 | GLS (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4CCR2 | |
| SCHEMBL6681771 | 0.87 | CCR2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4SYK | |
| SCHEMBL1022260 | 0.87 | GLS (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4CCR2 | |
| SCHEMBL29394473 | 0.86 | LCK (0.47) | LCK | |
| SCHEMBL20098837 | 0.86 | CDK5 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020133123-A1 | OXIME-TETRAZOLE DERIVATIVE AND APPLICATION THEREOF IN AGRICULTURE | 东莞市东阳光农药研发有限公司 | 2020-07-02 | — | — | WO | disclosed |
| US-9663460-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170050925-A9 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9371278-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9328067-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20160083342-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083342-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20140378492-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2014-12-25 | — | — | US | disclosed |
| US-8877804-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-8283442-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120190866-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8178491-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090257978-A1 | Antiviral coumpounds | GILEAD SCIENCES, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-7488748-B2 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-10 | — | — | US | disclosed |
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-02 | — | — | US | disclosed |
| EP-1590325-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067510-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083342-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | CHRNB2 2027/4885CHRNB4 1870/4885CHRNA3 2273/4885 |
| US-20090257978-A1 | Antiviral coumpounds | MAVS, ZC3HAV1, EIF2AK2 | CHRNB2 4880/4885CHRNB4 4876/4885CHRNA3 4869/4885 |
| US-20140378492-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | CHRNB2 2027/4885CHRNB4 1870/4885CHRNA3 2273/4885 |
| US-20170050925-A9 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | CHRNB2 2027/4885CHRNB4 1870/4885CHRNA3 2273/4885 |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | CHRNB2 2027/4885CHRNB4 1870/4885CHRNA3 2273/4885 |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CHRNB2 4885/4885CHRNB4 4876/4885CHRNA3 4873/4885 |
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | CHRNB2 45/4885CHRNB4 59/4885CHRNA3 17/4885 |
| US-20120190866-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CHRNB2 4885/4885CHRNB4 4876/4885CHRNA3 4873/4885 |
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CHRNB2 4885/4885CHRNB4 4876/4885CHRNA3 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.